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A B S T R A C TObjectives: The EuroQol ﬁve-dimensional (EQ-5D) questionnaire is a
generic measure widely used for the assessment of health status.
Research has suggested that it may be insensitive to the burdens
associated with particular conditions. This study was designed to
explore the feasibility of developing and valuing a disease-speciﬁc
“bolt-on” version of the EQ-5D questionnaire for use in psoriasis.
Methods: A series of steps were undertaken to develop, test, and
evaluate dimensions for a psoriasis-speciﬁc version of the EQ-5D
questionnaire (hereafter referred to as the EQ-PSO questionnaire).
Candidate dimensions were explored through a review of published
literature, in-depth qualitative interviews with patients, and consul-
tation with a clinical expert. A psychometric validation exercise was
then undertaken to establish how well dimensions functioned. Two
dimensions were selected for inclusion in a draft measure along-
side the existing EQ-5D questionnaire dimensions: “skin irritation”
and “self-conﬁdence.” Last, a time trade-off valuation exercise wassee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.10.003
nburn@iconplc.com.
ndence to: Paul Swinburn, Oxford Outcomes (ICONconducted with 300 members of the UK general public to derive utilities
for health states described by the measure. Results: The psychometric
analyses indicated that the two new candidate dimensions captured
additional variance over and above the existing ﬁve dimensions. Data
from the valuation exercise were analyzed by using different models. A
collapsed random effects model was put forward as a parsimonious
and accurate approach. Based on this model, estimated utilities ranged
from 0.98  0.02 for state “1111111” to 0.03  0.29 for state “5555555.”
Conclusions: This study has developed the EQ-PSO questionnaire to
support future psoriasis research and has informed the development of
future bolt-on versions of the EQ-5D questionnaire.
Keywords: disease-speciﬁc, economic evaluation, EQ-5D, health-
related quality of life, instrument development, psoriasis, utilities.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The EuroQol ﬁve-dimensional (EQ-5D) questionnaire is a stand-
ardized generic instrument used for describing and valuing
health status, which is scored as a single index ranging from 1
(full health) to 0 (dead) and below 0 for states worse than dead [1].
The single index is used to estimate quality-adjusted life-years
for cost-effectiveness analysis [2]. The original EQ-5D question-
naire was designed as a generic instrument with dimensions
relevant to all patient groups and the general population. Five
dimensions describe health (mobility, self-care, usual activities,
pain/ discomfort, and anxiety/ depression). For some conditions,
however, important aspects of a disease or symptom may not be
captured by these core dimensions of health and as such the EQ-
5D questionnaire may be insensitive in these conditions.
Research has been undertaken in different therapy areas to
explore the validity or sensitivity of the EQ-5D questionnaire[3–6]. In summary, this research has demonstrated limitations
with regard to vision, hearing, and some psychological disorders.
This has been recognized in the latest version of the National
Institute for Health and Care Excellence guidance for methods of
technology appraisal, which states, “In some circumstances,
evidence suggests that using the EQ-5D may not be valid (for
example in certain mental health conditions related to psychosis,
mania or cognition, or in conditions affecting sensory functions
like vision or hearing)” [7].
One solution that has been proposed to improve the validity
of the EQ-5D questionnaire is the inclusion of additional dimen-
sions that are designed to capture important elements of the
condition [8]. These so-called bolt-on measures would include
the standard EQ-5D questionnaire ﬁve dimensions with the
addition of one or more condition-speciﬁc dimension to address
the particular disease. Such an approach has the potential
advantage of retaining the core dimensions of the EQ-5Dociety for Pharmacoeconomics and Outcomes Research (ISPOR).
plc), Seacourt Tower, West Way, Oxford OX2 0JJ, UK.
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speciﬁc health conditions. It should also help to retain the
strengths of the current version of the EQ-5D questionnaire.
There has been relatively limited research so far on the
development of the EQ-5D questionnaire bolt-on measures. Some
work has been undertaken in cognitive problems, sensory impair-
ments, and difﬁculties related to sleep [9–11]. The present study
team also considered that there is inconclusive evidence for the
effectiveness of the EQ-5D questionnaire for use in dermatological
conditions [12,13]. Research into the impact of psoriasis has
shown that it can have a very signiﬁcant impact on patients’
health-related quality of life. One study reported that patients
were willing to accept a 40% shorter life expectancy to avoid
uncontrolled disease [14]. The nature of the speciﬁc burden tradi-
tionally associated with psoriasis (skin lesions, itch, embarrass-
ment, etc.) may not be reﬂected in the EQ-5D questionnaire
descriptive system and as such it may be an appropriate candidate
for the development of an EQ-5D questionnaire bolt-on module.
The EuroQol Group has an interest in the potential for the
development of bolt-on versions of the EQ-5D questionnaire. The
project reported here was designed to develop a psoriasis-speciﬁc
version of the EQ-5D questionnaire (the EQ-PSO questionnaire).
In addition, the project was designed to explore the feasibility of
methods for the development of bolt-on measures.Methods
The study comprised two main phases: the development and
psychometric testing of the bolt-on instrument and a subsequent
valuation exercise.
Phase 1: Development of the EQ-PSO Questionnaire Bolt-On
Instrument
The EQ-PSO questionnaire was speciﬁcally designed to retain all
the current ﬁve-level EQ-5D questionnaire (EQ-5D-5L) dimensions
(mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression), which would be supplemented with additional
disease-speciﬁc dimensions. The ﬁve-level version of the EQ-5D
questionnaire was chosen as the basis because it was hypothe-
sized that this would permit easier interpretation of the study
ﬁndings in the context of future research. To develop a condition-
speciﬁc version of the EQ-5D questionnaire, we sought to initially
identify important issues and concerns for patients with psor-
iasis through review of the available literature, and interviews
with clinicians and patients.
Literature review and clinician interview
Rather than undertaking a full systematic review, a more focused
literature review was conducted to understand the symptom and
treatment burden associated with psoriasis. The literature search
incorporated Medline, Embase, and other specialist databases
and was conducted by using OVID in March 2010. Articles were
restricted to those published in English between 1990 and 2010,
with particular attention paid to the identiﬁcation of articles that
used qualitative research methods to further examine patient
perspectives on the experience of psoriasis.
The literature review provided evidence regarding how psor-
iasis affects physical, psychological, and social well-being. Psori-
atic lesions are frequently itchy, but patients also experience
burning, stinging, pain, and bleeding [15]. Skin lesions may further
lead to disrupted sleep and can restrict the use of the hands [16].
The skin lesions associated with psoriasis can also be large in
area, raised from the normal surface of the skin, and visually
obvious. Studies have reported rates of depression in patients
with psoriasis ranging from 10% to 58% [17], with the severity ofdepression linked to the degree of skin area affected by psoriasis
[18]. People with more severe psoriasis are more likely to report
feeling anxious, hopeless, or ashamed [19]. Social contacts with
family, friends, and neighbors; physical activities; group activities;
going out socially; and going to public places can also be limited
by psoriasis [20]. Skin disease is additionally noted as leading
people to feel physically unattractive and/or sexually undesirable
[21]. Previous research has noted a genetic component to the
susceptibility of individuals to developing psoriasis [22].
An interview was conducted with a US-based dermatologist
who has experience of working with patients with psoriasis. An
interview discussion guide was developed on the basis of ﬁndings
from the literature. The dermatologist was asked to characterize
the nature of difﬁculties experienced by patients with respect to
their symptoms and in managing their disease.
The dermatologist described the impact of psoriasis in terms
of physical, social, and psychological difﬁculties, and how these
varied in terms of the extent and visibility of the disease. The
clinician described very common problems of skin irritation
including itching, which can lead to further irritation. The
psychosocial consequences of the condition could be severe,
with patients often reporting anxiety and/or depression due to
their skin complaints. The dermatologist also described how
patients often worried about the prospect of further disease
outbreaks or ﬂare-ups.
Patient interviews
To identify candidate dimensions for the psoriasis module, a
series of in-depth semi-structured qualitative interviews were
conducted in the United Kingdom (n ¼ 8) with individuals with
self-reported psoriasis at varying degrees of severity. The inter-
views were recorded and transcribed for qualitative analysis by
using the Atlas.ti (Scientiﬁc Soft., Berlin, Germany) software
package. A summary of the themes and typical quotes are
presented (Table 1); see also Lloyd et al. [23].
Psoriasis was reported as having a widespread effect on the
lives of patients with psoriasis. Most individuals experienced a
signiﬁcant degree of pain or discomfort directly attributable to
their condition. Frequent and often nonconscious scratching
could serve to aggravate lesions, resulting in soreness and
bleeding. This could result in sleep disturbance and daytime
fatigue from inadequate rest. The prescribed skin care routine of
some individuals was described as bothersome.
Some individuals reported an unwillingness to engage in social
activities in which their psoriasis would be more visible (e.g.,
swimming, sunbathing, or visiting hairdressers). Psoriasis often
resulted in embarrassment for patients, which affected self-
conﬁdence and self-esteem. Most participants also reported anxiety
and/or depression because of their psoriasis as well as feelings of
frustration due to their inability to successfully control the disease.
Two of the participants were diagnosed with psoriatic arthri-
tis. These patients experienced arthritic problems of pain and
loss of mobility. They did however report experiencing similar
concerns related to their skin (although these were of secondary
importance when compared with the very severe consequences
related to arthritis).
Identiﬁcation of candidate dimensions
The ﬁndings from the literature review and interviews were used
to draft four new dimensions: skin irritation (including itching),
skin appearance (e.g., redness, dry skin, and ﬂakiness), self-
conﬁdence, and social/relationship difﬁculties (e.g., embarrass-
ment, relationship problems). These dimensions reﬂected the
ﬁndings from the qualitative research. New dimensions were
chosen to minimize any overlap with existing EQ-5D question-
naire dimensions. The language of new dimensions and their
Table 1 – Qualitative evidence supporting the proposed candidate dimensions.
Themes Sample quotes Candidate
dimensions
Physical impact of psoriasis symptoms “… the itching can drive you mad. You just can’t scratch it.” Skin irritation
“It’s not like a normal itch. […] It’s like it is right inside your
skin.”
Desire to cover up psoriasis lesions “It just makes me look gross.” Skin appearance
“It is not nice to have bad skin […] I do feel less physically
attractive because of it.”
Intrapersonal psychological impact “I feel like there is something really wrong with me.” Self-conﬁdence
“… it’s just embarrassing. You’re too busy being conscious of
yourself …”
Interpersonal psychological impact; avoidance
of social situations
“If it gets very bad then I just won’t get close to people.” Social/relationship
difﬁculties“I’d rather just be at home. I’d rather just stay out of people’s
way.”
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and was chosen to avoid translation problems.
Cognitive debrieﬁng of candidate dimensions
The candidate dimensions were examined in cognitive debrieﬁng
interviews (n ¼ 10) with patients with questionnaire. A cognitive
debrieﬁng guide was used to assess the suitability of the proposed
dimensions for inclusion in the new measure. The interviews
assessed whether the concepts were important to patients, whether
patients thought the language used was appropriate, and whether
people thought the response options were suitable. Findings from
the cognitive debrieﬁng interviews suggested that all candidate
dimensions were identiﬁed as reﬂecting legitimate concerns for
patients with psoriasis. Individuals reported good understanding of
the descriptions of different dimensions and response options. All
participants expressed the opinion that candidate dimensions were
appropriate for inclusion in the intended measure and were not
intrusive or likely to cause discomfort for respondents.
Psychometric validation
An initial assessment of the psychometric performance of the
candidate dimensions was undertaken. One hundred individuals
in the United Kingdom with varying severity of psoriasis were
recruited and completed the EQ-5D-5L questionnaire instrument
plus the four psoriasis dimensions. Participants also completed
two additional dermatology-speciﬁc measures to permit assess-
ment of item functioning: the Dermatology Life Quality Index
(DLQI) [24] and the Self-Administered Psoriasis Area and Severity
Index (SAPASI) [25].
Phase 2: Valuation of the EQ-PSO Questionnaire Bolt-On
Instrument
To generate the EQ-5D-PSO questionnaire value set, a series of
valuation interviews were undertaken with a sample of the UK
general public. A convenience sample was recruited to match the
demographic proﬁle of the United Kingdom. Participants were
aged at least 18 years, currently resident in the United Kingdom,
able to understand the interview as judged by the interviewer,
and able to give informed consent. People were to be excluded if
at the screening phase they reported that they had an acute
illness or cognitive impairment that in the opinion of the inves-
tigator would interfere with the study requirements. Face-to-face
interviews were undertaken by trained experienced interviewers.
Interview participants completed a sociodemographic form,
the EQ-5D-5L questionnaire, and the time trade-off (TTO) inter-
view [26]. Participants were randomly allocated to assess one of
ﬁve blocks of health states. Each participant was asked to rate 11health states that varied in terms of the seven EQ-PSO question-
naire dimensions. The selection of health states was based on an
orthogonal array that included 49 states plus four additional
states (comprising of a level 1 problem on all dimensions, level 5
problem on all dimensions, and either a level 1 problem or a level
5 problem on the newly added dimensions.
Participants rated each state by using a 100-point visual ana-
logue scale (VAS) anchored at best imaginable health (100) and
worst imaginable health (0). Participants also rated a state described
as “dead.” This task provided participants with an introduction to
the concept of rating health states and also provided an indication
of which states participants assessed as worse than dead.
In the TTO exercise, participants were ﬁrst asked to rate all
states that were assessed as better than dead (i.e., scored above
dead on the VAS). The TTO procedure used 10 years as the time
horizon and the time in full health iterated between 10 years,
then 1 year, then 9 years, and so on. An indifference point was
inferred if participants’ preference switched or if they indicated
that the two prospects were the same. The procedure did not
iterate below a time period of 6 months. A modiﬁed approach was
undertaken to assess states that had been rated as worse than
dead. This required participants to rate a given state as being
equal to or lower than dead on the VAS. In this instance, the
trade-off occurs between being dead and spending time in a
particular state followed by a period of full health. Interviewers
used a crib sheet to determine the rating for each state.
Written informed consent was obtained from all participants
before study initiation, and the study protocol underwent inde-
pendent ethical review. Participants in the study received £25
compensation. Participants’ data were excluded on the grounds
of rationality if they scored the same value for all health states, if
respondents valued two or more health states higher than
1111111, or if respondents valued two or more health states
lower than 5555555.Results
Psychometric Validation
Analyses were undertaken to assess the psychometric properties
of the new instrument. Exploratory factor analysis was used to
examine the underlying factor structure of the measure and to
explore the potential for item reduction (using direct oblimin
rotation). This analysis indicated that two of the dimensions—
skin irritation and self-conﬁdence (Fig. 1)—emerged as separate
factors and were more important predictors of the measure
variance than the other two candidate dimensions, which were
subsequently dropped.
Fig. 1 – Psoriasis-speciﬁc dimension descriptions.
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the ability of the EQ-5D questionnaire (with or without the
additional candidate dimensions) to predict scores on the DLQI
and SAPASI (Table 2). For the DLQI, the explanatory power of the
model (measured by R2) increased from 0.422 to 0.646 when the
psoriasis-speciﬁc dimensions were added as independent varia-
bles. For SAPASI, the explanatory power increased from 0.182 to
0.445 when the psoriasis-speciﬁc dimensions were added.Valuation Data Analysis
A number of different post hoc modeling approaches to the
valuation data were attempted. The initial models used ordinary
least squares (OLS) and random effects (RE) approaches in
explaining the TTO-derived utility. The performance of these
models was compared by using different ﬁt statistics includingTable 2 – Regression coefﬁcients for the two EQ-5D ques
Model Dimension
1 (Constant)
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression
2 (Constant)
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression
Skin irritation
Skin appearance
Self-conﬁdence
Social/relationship difﬁculties
DLQI, Dermatology Life Quality Index; EQ-5D, EuroQol ﬁve-dimensional;root mean squared error and adjusted R2. Analyses were also
conducted to examine the presence of logical inconsistencies.
In addition to the initial approaches, a series of other models
were also explored including Tobit, loglinear, and two-stage
modeling. Numerous different interaction models were also
attempted, using full factorial ﬁrst-order interactions bet-
ween dimensions as a whole, and using level 4 and level 5
interactions between dimensions. Also, models with N2, N3, N4,
N5 (any impairment at level 2, level 3, etc.) terms were contrasted
with models with at least two level 4s, at least three level 4s, at
least two level 5s, at least three level 5s, at least two level 4s OR 5s,
at least three level 4s OR 5s, and so on. Analyses were exploratory
in nature, and only a summary of the ﬁnal models is presented.
EQ-PSO questionnaire utilities were estimated from an avail-
able data set to explore how they varied in line with established
SAPASI and DLQI severity gradings [27] for patients with psoriasis
(Table 3). The mean utilities were also compared with EQ-5D-5L
questionnaire values [28].Valuation Results
Three hundred valuation interviews were completed. The data
set had no missing data, and very few states rated as worse than
dead (1.2% of all responses). There were also no nontraders for
TTO (i.e., no respondents scored 1 for all health states). Seven
respondents were excluded for failing rationality tests.TTO Modeling Results
The main-effects OLS and RE models (models 1 and 2; Table 4)
generally show good results; almost all parameter values are
signiﬁcant, and most coefﬁcients are in the right order. For usual
activities, levels 2 and 3 are almost identical, and for self-
conﬁdence, levels 2 and 3 are reversed but both are not signiﬁ-
cant. The RE model shows a much better ﬁt, with a root mean
squared error of 0.197 versus 0.255 for the OLS model. Both new
dimensions have a signiﬁcant impact on participants’ strength oftionnaire models predicting DLQI and SAPASI scores.
P
DLQI score SAPASI score
0.417 0.836
0.126 0.917
0.107 0.405
0.239 0.088
0.214 0.021
o0.001 0.009
o0.001 o0.001
0.071 0.895
0.188 0.685
0.273 0.097
0.656 0.091
0.484 0.394
0.013 0.029
0.002 0.001
0.015 0.071
0.111 0.461
Model 1 R2 ¼ 0.422 Model 1 R2 ¼ 0.182
P o 0.001 P ¼ 0.002
Model 2 R2 ¼ 0.646 Model 2 R2 ¼ 0.445
P o 0.001 P o 0.001
SAPASI, Self-Administered Psoriasis Area and Severity Index.
Table 3 – The EQ-5D-PSO questionnaire utility values
stratiﬁed by DLQI and SAPASI scores (n ¼ 100).
N Mean SD
EQ-5D-PSO EQ-5D-5L*
All patients 100 0.75  0.17 0.71  0.26
DLQI
0–1 10 0.83  0.14 0.82  0.23
2–5 35 0.82  0.12 0.80  0.23
6–10 23 0.76  0.13 0.75  0.21
11–20 26 0.71  0.11 0.65  0.20
21–30 6 0.38  0.28 0.20  0.33
SAPAPSI
o3 33 0.84  0.10 0.83  0.19
3–15 50 0.75  0.12 0.71  0.23
>15 17 0.59  0.26 0.50  0.36
DLQI, Dermatology Life Quality Index; EQ-5D-5L, ﬁve-level Euro-
Qol ﬁve-dimensional; EQ-5D-PSO, EuroQol ﬁve-dimensional
psoriasis; SAPASI, Self-Administered Psoriasis Area and
Severity Index.
 EQ-5D-5L crosswalk values for the United Kingdom [28].
Table 4 – Coefﬁcients derived from TTO models 1 and 2 (d
based on collapsed levels.
Dimension Model 1 Model 2
OLS RE
MO2 0.027 0.024 M
MO3 0.047 0.045 M
MO4 0.122 0.133 M
MO5 0.169 0.160 M
SC2 0.026 0.024 S
SC3 0.047 0.049 S
SC4 0.115 0.110 S
SC5 0.101 0.106
UA2 0.035 0.035 U
UA3 0.034 0.036 U
UA4 0.124 0.129
UA5 0.116 0.116
PD2 0.029 0.029 P
PD3 0.037 0.036 P
PD4 0.210 0.204 P
PD5 0.201 0.210
AD2 0.016* 0.015* A
AD3 0.034 0.039 A
AD4 0.158 0.160 A
AD5 0.140 0.141
SI2 0.054 0.053 S
SI3 0.045 0.044 S
SI4 0.097 0.101 S
SI5 0.133 0.124
SE2 0.018* 0.020* S
SE3 0.004* 0.011* S
SE4 0.088 0.091
SE5 0.066 0.078
Constant 0.069 0.067
Adjusted R2 0.319 0.324
RMSE 0.255 0.197
AD, anxiety/depression; MO, mobility; OLS, ordinary least squares; PD, pa
self-care; SE, self-conﬁdence; SI, skin irritation; TTO, time trade-off; UA,
 Nonsigniﬁcant (P 4 0.05).
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impact of the seven dimensions but is still signiﬁcant.
Level 4 and 5 “reversals”
It should be noted that for ﬁve dimensions for the OLS model and
four dimensions for the RE model, level 4 has a higher disutility
than level 5, but level 4 and 5 parameter values are not statistically
signiﬁcantly different. There is very little evidence, however, of
differentiation between levels 4 and 5 in the expected direction.
Collapsed RE model
The presence of inconsistencies in the utility weights from the
present study is a signiﬁcant issue. Analyses were run with levels
collapsed to address this problem (levels 4 and 5 dimension
scores, and levels 2 and 3 for skin irritation and self-conﬁdence).
This resulted in a model with 22 parameters and a constant with
similar model-adjusted R2 and root mean squared error values
compared with other models that were tested (models 3 and 4;
Table 4).
Other models
Many other models including Tobit, loglinear, and two-stage
modeling were explored, but ﬁndings are not reported here. Fitummy model) by using OLS and RE and models 3 and 4
Model 3 Model 4
OLS RE
O2 0.028 MO2 0.025
O3 0.047 MO3 0.046
O4 0.123 MO4 0.135
O5 0.166 MO5 0.159
C2 0.026 SC2 0.023
C3 0.047 SC3 0.050
C45 0.107 SC45 0.108
A23 0.035 UA2 0.034
A45 0.119 UA3 0.036
UA45 0.122
D2 0.029 PD2 0.031
D3 0.038 PD3 0.036
D45 0.205 PD4 0.201
PD5 0.207
D2 0.017* AD2 0.015*
D3 0.035 AD3 0.040
D45 0.148 AD45 0.151
I23 0.052 SI23 0.052
I4 0.099 SI4 0.103
I5 0.131 SI5 0.123
E23 0.013* SE23 0.016*
E45 0.074 SE45 0.084
0.069 0.066
0.319 0.323
0.255 0.197
in/discomfort; RE, random effects; RMSE, root mean square error; SC,
usual activities.
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Fig. 2 – Mean observed versus predicted utility values.
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increasingly complex models, these were abandoned. Many
models including interaction variables were explored, but most
interaction variables were nonsigniﬁcant. Backward and forward
regression was used to explore patterns of interaction, but
although some level 4 and level 5 variables were signiﬁcant, no
clear patterns were found.
The collapsed RE model is proposed as the best model for
estimating preference weights for the EQ-5D-Psoriasis question-
naire. Figure 2 shows the predictive ability of the model against
observed data.Discussion
This report describes the ﬁndings from a study designed to
develop a psoriasis-speciﬁc bolt-on version of the EQ-5D ques-
tionnaire. The EQ-PSO questionnaire was partly conceived as a
study to explore the feasibility and methods for developing bolt-
ons that would permit more effective economic evaluations in
speciﬁc disease areas (rather than as a replacement for disease-
speciﬁc measures in clinical practice). We believe that there are
some useful ﬁndings from this work that can inform the debate
regarding the development of bolt-ons.
The development of bolt-ons or disease-speciﬁc versions of the
EQ-5D questionnaire must be driven by evidence that the existing
EQ-5D questionnaire has some limitations in a speciﬁc context.
Different methods have been suggested for exploring this issue.
Longworth et al. [13] previously used systematic reviews of the EQ-
5D questionnaire data to identify disease areas in which it is
insensitive. Other methods based on exploring discrepancies
between single-index and VAS scores may also be possible. In the
present study, however, the need for a psoriasis-speciﬁc version of
the EQ-5D questionnaire was primarily explored by using qualitative
research with patients with psoriasis. The ﬁndings outlined above
highlighted how important elements of their health status were not
currently captured by the EQ-5D questionnaire. The qualitative
research also informed the development of the additional dimen-
sions. We recommend that future development of bolt-onmeasures
should be informed by in-depth qualitative research with patients
to ensure that the most appropriate issues are captured and that
the new dimensions are described in an optimal way.
The second stage of the development process of the new
instrument was a psychometric validation study. People with
psoriasis completed the EQ-PSO questionnaire and other meas-
ures. The validation study found evidence that the additional
dimensions were capturing important additional information.
The regression analysis showed that the new measure was much
better at predicting psoriasis outcomes (DLQI and SAPASI) when
compared with the unmodiﬁed EQ-5D questionnaire. Theexploratory factor analysis identiﬁed that skin irritation and skin
appearance grouped together, while self-conﬁdence and social/
relationship difﬁculties loaded on a separate factor. The factor
loadings and other psychometric analyses were also used to
identify two dimensions that could be dropped. We believe that
this is also a useful step for identifying the most salient or
important additional dimensions to include in a bolt-on. There is
only limited scope for adding dimensions to the EQ-5D question-
naire (because of econometric constraints) and so selecting the
most appropriate dimension is very important.
The ﬁnal stage in this instrument development was the
collection of preference weights so that a single index score can
be estimated from the measure. We used a slightly modiﬁed
version of the TTO exercise that was used in the original EQ-5D
questionnaire valuation work. The selection of states was based
on an orthogonal design, which was one important difference.
Three hundred face-to-face interviews were completed by using
skilled interviewers. This resulted in very high data quality, with
very little missing data and only 2% of people excluded for failing
tests of rationality. A substantial amount of analysis work was
undertaken on the data set, of which only a small proportion is
presented here. The initial analyses failed to reliably differentiate
between some of the levels of each dimension—in particular,
levels 4 and 5. Therefore, it was decided that these response
options should be collapsed in the modeling. A lot of work was
undertaken including interaction terms and constants, but it was
concluded that this did not improve the explanatory power of the
models. The ﬁnal model that was agreed by the study team was a
collapsed version of the RE model. Subsequent analyses based on
this model show how well it can predict observed data (Fig. 2) and
differences in psoriasis severity (Table 3).
This study highlights an important issue in the development
of bolt-ons related to the role of the existing ﬁve dimensions. The
data analyses have estimated coefﬁcient weights for the existing
ﬁve dimensions of the EQ-5D questionnaire as well as the two
new dimensions. The analyses show that in this study the ﬁve
original dimensions have different weights compared with other
studies (e.g., van Hout et al. [28]). In future analyses, we will
explore the effect of maintaining the existing ﬁve dimension
weights constant (based on the ongoing EQ-5D-5L questionnaire
valuation work) and using the analysis to estimate weights only
for the two additional dimensions.
There are a number of important limitations in this study
that should be considered. First, the study was primarily
designed to explore methodological feasibility for the develop-
ment of bolt-ons. There are opportunities for understanding
more about the performance of the measure, including the use
of the EQ-PSO questionnaire as compared with the use of
disease-speciﬁc measures such as the DLQI, as well as the
responsiveness of the EQ-PSO questionnaire to change in
health status. Second, the initial literature review undertaken
was not systematic in nature but rather focused on the
identiﬁcation of key issues for patients with psoriasis. Third,
various aspects of the study may also be limited in part by
sample size. The initial qualitative work, the psychometric
validation study, and valuation work may all have been limited
by their sample size to an extent. While only eight qualitative
interviews were completed, however, we found that no sub-
stantial new information was emerging from the interviews.
On the basis of additional analysis, we also believe that the
ﬁndings from the psychometric validation work would not
have changed substantially with a larger sample size. The lack
of differentiation between levels of the EQ-PSO questionnaire
may have emerged as a result of insufﬁcient data. Fourth, there
may have been value in collecting additional data around
patients’ prescription drug use as the potential exists for some
bias to have been introduced by side effects associated with
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 5 6 – 1 1 6 21162immunomodulatory drugs impacting reported health status.
Last, we note that the comparison of EQ-5D-5L questionnaire
and EQ-PSO questionnaire–derived utilities in Table 3 is not
straightforward because the 5L utilities are based on a mapping
to the EQ-5D-3L questionnaire while EQ-PSO questionnaire
values are based on a de novo valuation study. Therefore, it
is not possible to conclude from this comparison whether the
EQ-PSO questionnaire is more sensitive than the EQ-5D
questionnaire.
This work has tested methods for the development and
valuation of a disease-speciﬁc version of the EQ-5D question-
naire. Furthermore, the work has provided a direction and insight
into potential future EQ-5D questionnaire bolt-on research. Last,
the EQ-PSO questionnaire instrument may prove valuable for the
future of research demonstrating the burden associated with
psoriasis.
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